(Q24240646)

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

Role of antiparasitic therapy for seizures and resolution of lesions in neurocysticercosis patients: an 8 year randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

Single-day praziquantel versus 1-week albendazole for neurocysticercosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

Serologic evolution of neurocysticercosis patients after antiparasitic therapy. Cysticercosis Working Group in Peru

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Cysticercosis Working Group in Peru.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

Neurocysticercosis in childhood. II. Computed tomography of 24 patients according to symptomatic and praziquantel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

Optimization of the single-day praziquantel therapy for neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

Therapy for neurocysticercosis. Comparison between albendazole and praziquantel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

Is the course of neurocysticercosis modified by treatment with antihelminthic agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Albendazole vs praziquantel for therapy for neurocysticercosis. A controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

WITHDRAWN: Drugs for treating neurocysticercosis (tapeworm infection of the brain).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Neurocysticercosis: optimal dose treatment with albendazole

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Albendazole versus praziquantel in the treatment of cerebral cysticercosis: clinical evaluation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Efficacy of a 3-day course of albendazole treatment in patients with a single neurocysticercosis cyst

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Randomized controlled trial of albendazole in new onset epilepsy and MRI confirmed solitary cerebral cysticercal lesion: effect on long-term seizure outcome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Efficacy of albendazole and short-course dexamethasone treatment in children with 1 or 2 ring-enhancing lesions of neurocysticercosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Neurocysticercosis in children: clinical findings and response to albendazole therapy in a randomized, double-blind, placebo-controlled trial in newly diagnosed cases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Short regimen of praziquantel in the treatment of single brain enhancing lesions.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Morphometry of single small enhancing computed tomographic lesions: outcome and effect of albendazole therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized, placebo-controlled, double blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Effect of anticysticercal treatment on the prognosis of epilepsy in neurocysticercosis: a pilot trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

1 reference

7 January 2021

Current consensus guidelines for treatment of neurocysticercosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Systematic reviews in health care: Assessing the quality of controlled clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Pre-treatment with corticosteroids and a single cycle of high dose albendazole for subarachnoidal cysticercosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Corticosteroids versus albendazole for treatment of single small enhancing computed tomographic lesions in children with neurocysticercosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Does albendazole affect seizure remission and computed tomography response in children with neurocysticercosis? A Systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Albendazole in single CT ring lesions in epilepsy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Calcified neurocysticercotic lesions and postsurgery seizure control in temporal lobe epilepsy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

[Treatment of neurocysticercosis: a review]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

Economic evaluation of seizures associated with solitary cysticercus granuloma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000215.PUB3

7 January 2021

10.1002/14651858.CD000215.PUB3

Identifiers

DOI

0 references

Fatcat ID

release_ofcysecmivcg3nbgxooxoivax4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ofcysecmivcg3nbgxooxoivax4

24 November 2022